Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) today announced the
appointment of George S. Golumbeski, Ph.D., to its Board of Directors.
Dr. Golumbeski will also serve as a member of the Compensation Committee
and the Nominating and Corporate Governance Committees.
“Dr. Golumbeski’s professional experience in business development
coupled with his scientific expertise will serve Enanta well as we
continue to advance our internal programs and prepare to broaden our
pipeline focus,” stated Jay R. Luly, Ph.D. President and Chief Executive
Officer. “I look forward to his guidance and leadership on our Board.”
Dr. Golumbeski has nearly 20 years’ senior executive and business
development experience in the pharmaceutical and biotechnology industry.
Since 2009 he has served as Senior Vice President, Business Development
at Celgene Corporation, a global biopharmaceutical company engaged in
the discovery, development and commercialization of novel therapies for
the treatment of cancer and inflammatory diseases, where he is
responsible for business development, M&A, licensing, and partnership
activities. Prior to Celgene, he was appointed Chief Executive Officer
at Nabriva Therapeutics AG, where from 2008-2009 he redirected the
company’s efforts and led the transition toward a development company.
From 2002 to 2008, Dr. Golumbeski was Vice President, Business
Development, Licensing and Strategy at Novartis-Oncology, a business
unit within Novartis where he was a member of the Executive Committee
which was responsible for the overall results of the business unit
franchise. Previously he served as Vice President, Research and
Development at Elan Biopharmaceuticals, where from 2001-2002 he was a
member of the research and development management team primarily
responsible for the research and development pipeline and drug candidate
selection.
Earlier in his career, he held several business and corporate
development positions of increasing responsibility at EMD
Pharmaceuticals, Schwarz Pharma, Pierce Chemical Company and Promega
Corporation.
Dr. Golumbeski received a B.A. in Biology from the University of
Virginia, and a Ph.D. in Genetics from the University of
Wisconsin-Madison. He completed his postdoctoral research in molecular
biology at the University of Colorado-Boulder.
About Enanta
Enanta Pharmaceuticals is a research and development-focused
biotechnology company that uses its robust chemistry-driven approach and
drug discovery capabilities to create small molecule drugs in the
infectious disease field. Enanta is discovering, and in some cases
developing, novel inhibitors designed for use against the hepatitis C
virus (HCV). These inhibitors include members of the direct acting
antiviral (DAA) inhibitor classes – protease (partnered with AbbVie),
NS5A (partnered with Novartis) and nucleotide polymerase – as well as a
host-targeted antiviral (HTA) inhibitor class targeted against
cyclophilin. Additionally, Enanta has created a new class of
antibiotics, called Bicyclolides, for the treatment of multi-drug
resistant bacteria, with a focus on developing an intravenous and oral
treatment for hospital and community MRSA (methicillin-resistant Staphylococcus
aureus) infections.
Copyright Business Wire 2014